Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

IMA new masthead1

October 30, 2014

View Archives Issues

  • LDL Levels — Are Fasting Blood Specimens Necessary?

    Doran B, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: Insight from the National Health and Nutrition Examination Survey III
  • Migraines: Much More Complicated Than Just a Headache

    Migraine is associated with multiple disorders, including irritable bowel syndrome, restless legs syndrome, and non-alcoholic fatty liver disease. Understanding how these disparate disorders link to migraine may lead to an increased understanding of the pathogenesis of this complex neurological condition.
  • Angiotensin Receptor Blockers for Hypertension

    Makani H, et al. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: A meta-analysis.
  • Naloxegol Tablets (Movantik ¢â )

    The FDA has approved a mu-opioid receptor antagonist for the treatment of opioid-induced constipation (OIC). Naloxegol is a pegylated derivative of naloxone which acts on peripheral (e.g., gut) mu-receptors. It is marketed by AstraZeneca Pharmaceuticals as Movantik.
  • Hepatitis C Treatment: Just How Much is it Worth to Cure a Dreadful Disease?

    The trouble with the expense of treating hepatitis C virus (HCV) infections is that very few patients are acutely choking on it, since the largest pool of HCV patients are asymptomatic. Progression to end-stage liver disease, liver transplantation, and hepatocellular carcinoma the three most dreaded HCV consequences may seem distant to the asymptomatic or even modestly symptomatic patient.